postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome

ORPHA: 4776732 Treatments Available

Overview

human disease

Available Treatments (2)

DrugFormStatusCountriesLead Time
Baclofen
Oral tablets 10mg, 20mg; Intrathecal injection 0.05mg/mL, 10mg/20mLFDA Approved77d
tizanidine
oral tablet 2mg, 4mg; oral capsule 2mg, 4mg, 6mgFDA Approved45d

Clinical Presentation

Signs and symptoms associated with postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome, sourced from HPO and Orphanet clinical annotations.

MicrocephalyLow-set earsHypotelorismDelayed speech and language developmentIntellectual disabilitySpastic paraplegiaDysarthriaGlobal developmental delayGait disturbanceHyperreflexiaBroad-based gaitDroolingBabinski signSevere muscular hypotoniaNasogastric tube feeding in infancyNarrow foreheadSeizureTremorFailure to thriveHypoplasia of the corpus callosumFebrile seizure (within the age range of 3 months to 6 years)Abnormal CNS myelination

Classification & Codes

Orphanet Code

ORPHA:477673
postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome
OrphanetORPHA:477673
Treatments2 drug(s)
Symptoms on record22 signs
Statuspublished

Treatment Summary

Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO